Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid ...